First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study

Annals of Oncology

Volumn 9, Issue 3, 1998, Pages 331-334

  Georgoulias, V ^a,e   Androulakis, N ^a   Dimopoulos, A M ^b   Kourousis, C ^a   Kakolyris, S ^a   Papadakis, E ^c   Apostolopoulou, F ^d   Papadimitriou, C ^b   Vossos, A ^c   Agelidou, M ^d   Heras, P ^a   Tzannes, S ^c   Vlachonicolis, J ^a   Mavromanolakis, E ^a   Hatzidaki, D ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d SISMANOGLIO HOSPITAL   (Greece)

^e UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; VOMITING;

EID: 7144229342     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008278103446     Document Type: Article

References (15)

1. Mangatal L, Adeline MT, Guenard D et al. Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of Taxol and analogues. Tetrahedron 1989; 45: 4177-90.
2. Gueritte-Voegelein F, Guenard D, Lavelle F et al. Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 1991; 34: 992-8.
3. Fossella FV, Lee JS, Murphy WK et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 1238-44.
4. 2 with prednisone premedication for patients with advanced non-small-cell lung cancer. Cancer 1995; 75: 968-72.
5. Gerny T, Kaplan S, Pavlidis N et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer. A phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 1994; 70: 384-7.
6. Fossella FV, Lee JS, Shin DM et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995; 13: 645-51.
7. Donnadieu N, Paesmans M, Sculier JP. Chemotherapy of non-small-cell lung cancer according to disease extent: A meta-analysis of the literature. Lung Cancer 1991; 7: 243-52.
8. Albain KS, Growley JJ, Le Blanc M et al. Survival determinants in extensive-stage non-small-cell lung cancer. The Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-26.
9. Bissery MC, Nohyneck G, Sanderink GH et al. Docetaxel (Taxotere): A review of preclinical and clinical experience. Part I: Preclinical experience. Anti-Cancer Drugs 1995; 6: 339-68.
10. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
11. Pronk LC, Schellens JHM, Planting AST et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997; 15:1071-9.
12. Zalcberg J, Bishop JE, Webster LK et al. A phase I trial of the combination Taxotere (docetaxel) and cisplatin in patients with advanced non-small-cell lung cancer. In Meeting of the European Society (ESMO), Lisbon. Ann Oncol 1994; 5 (Suppl 8).
13. Cole JT, Gralla RJ, Marques CB et al. Phase I II study of cisplatin and docetaxel (Taxotere) in non-small-cell lung cancer. Proc Am Soc Clin Oncol 1993; 17: 357 (Abstr).
14. Berille J, Le Chevalier T, Zalcberg JR et al. Overview on Taxotere cisplatin (TXT-CDDP) combination in non-small-cell lung cancer (NSCLC). In Meeting of the European Society of Medical Oncology. Vienna. Ann Oncol 1996; 7 (Suppl 5): 90.
15. Viallet J, Laberge F, Martins H et al. Docetaxel alternating with cisplatin and vinorelbine: Early evidence of additive activity in a phase II trial of non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1996; 15: 375 (Abstr).